Phio Pharmaceuticals Corp.
PHIO
$1.98
-$0.16-7.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -44.44% | -50.06% | -37.15% | -46.93% | -28.72% |
| Gross Profit | 44.44% | 50.06% | 37.15% | 46.93% | 28.72% |
| SG&A Expenses | -14.25% | -18.98% | -20.12% | -18.61% | -1.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.95% | -35.77% | -30.35% | -25.10% | -6.67% |
| Operating Income | 30.95% | 35.77% | 30.35% | 25.10% | 6.67% |
| Income Before Tax | 33.96% | 36.38% | 30.37% | 24.61% | 5.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.96% | 36.38% | 30.37% | 24.61% | 5.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.96% | 36.38% | 30.37% | 24.61% | 5.70% |
| EBIT | 30.95% | 35.77% | 30.35% | 25.10% | 6.67% |
| EBITDA | 30.61% | 35.54% | 30.22% | 25.04% | 6.58% |
| EPS Basic | 81.21% | 79.51% | 74.02% | 65.98% | 36.66% |
| Normalized Basic EPS | 81.08% | 80.02% | 74.43% | 66.36% | 37.07% |
| EPS Diluted | 81.20% | 79.52% | 74.03% | 65.99% | 36.69% |
| Normalized Diluted EPS | 81.08% | 80.02% | 74.43% | 66.36% | 37.07% |
| Average Basic Shares Outstanding | 240.32% | 226.98% | 183.97% | 157.95% | 83.00% |
| Average Diluted Shares Outstanding | 240.32% | 226.98% | 183.97% | 157.95% | 83.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |